Free Trial

SciSparc (SPRC) Competitors

$1.13
-0.03 (-2.59%)
(As of 05/24/2024 ET)

SPRC vs. VRPX, SBFM, CMRA, BLPH, HSTO, EVFM, SXTC, ADTX, BPTH, and ALLR

Should you be buying SciSparc stock or one of its competitors? The main competitors of SciSparc include Virpax Pharmaceuticals (VRPX), Sunshine Biopharma (SBFM), Comera Life Sciences (CMRA), Bellerophon Therapeutics (BLPH), Histogen (HSTO), Evofem Biosciences (EVFM), China SXT Pharmaceuticals (SXTC), Aditxt (ADTX), Bio-Path (BPTH), and Allarity Therapeutics (ALLR). These companies are all part of the "pharmaceutical preparations" industry.

SciSparc vs.

Virpax Pharmaceuticals (NASDAQ:VRPX) and SciSparc (NASDAQ:SPRC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability, community ranking and analyst recommendations.

Virpax Pharmaceuticals' return on equity of 0.00% beat SciSparc's return on equity.

Company Net Margins Return on Equity Return on Assets
Virpax PharmaceuticalsN/A -345.87% -161.82%
SciSparc N/A N/A N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Virpax Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
SciSparc
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

32.2% of Virpax Pharmaceuticals shares are held by institutional investors. Comparatively, 25.1% of SciSparc shares are held by institutional investors. 6.2% of Virpax Pharmaceuticals shares are held by insiders. Comparatively, 1.5% of SciSparc shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

SciSparc has higher revenue and earnings than Virpax Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virpax PharmaceuticalsN/AN/A-$15.19MN/AN/A
SciSparc$2.88M0.28-$5.12MN/AN/A

In the previous week, Virpax Pharmaceuticals had 2 more articles in the media than SciSparc. MarketBeat recorded 4 mentions for Virpax Pharmaceuticals and 2 mentions for SciSparc. SciSparc's average media sentiment score of 0.19 beat Virpax Pharmaceuticals' score of 0.00 indicating that Virpax Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Virpax Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
SciSparc
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Virpax Pharmaceuticals and SciSparc both received 2 outperform votes by MarketBeat users.

CompanyUnderperformOutperform
Virpax PharmaceuticalsOutperform Votes
2
66.67%
Underperform Votes
1
33.33%
SciSparcOutperform Votes
2
66.67%
Underperform Votes
1
33.33%

Virpax Pharmaceuticals has a beta of 1.56, suggesting that its stock price is 56% more volatile than the S&P 500. Comparatively, SciSparc has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500.

Summary

Virpax Pharmaceuticals beats SciSparc on 5 of the 9 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SPRC vs. The Competition

MetricSciSparcPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$802,000.00$6.81B$5.20B$8.06B
Dividend YieldN/A2.67%2.83%3.93%
P/E RatioN/A21.27152.1518.19
Price / Sales0.28259.912,464.4379.80
Price / CashN/A36.7936.3031.61
Price / Book0.085.865.444.60
Net Income-$5.12M$132.39M$106.24M$214.07M
7 Day Performance-7.38%-2.40%-1.33%-1.08%
1 Month Performance-6.61%1.64%2.76%3.20%
1 Year Performance-92.71%-6.49%3.39%7.84%

SciSparc Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRPX
Virpax Pharmaceuticals
0 of 5 stars
$0.74
-3.9%
N/A-91.0%$867,000.00N/A0.007Analyst Forecast
News Coverage
Gap Down
High Trading Volume
SBFM
Sunshine Biopharma
2.7627 of 5 stars
$0.81
-17.4%
$260.00
+32,174.1%
-98.9%$798,000.00$24.09M-0.0444Gap Down
High Trading Volume
CMRA
Comera Life Sciences
0 of 5 stars
$0.03
flat
N/A-95.3%$899,000.00$630,000.00-0.0612Gap Up
BLPH
Bellerophon Therapeutics
1.0911 of 5 stars
$0.06
flat
$2.00
+3,101.0%
-99.3%$764,000.00N/A-0.0718Analyst Forecast
News Coverage
Gap Down
HSTO
Histogen
0 of 5 stars
$0.17
flat
N/A-81.9%$726,000.00$19,000.00-0.067Gap Up
EVFM
Evofem Biosciences
0 of 5 stars
$0.01
flat
N/A-98.5%$970,000.00$18.22M0.0037Gap Down
SXTC
China SXT Pharmaceuticals
0 of 5 stars
$1.14
-5.8%
N/A-82.5%$524,000.00$1.97M0.0078Positive News
Gap Down
ADTX
Aditxt
1.3105 of 5 stars
$2.08
-0.5%
$61.00
+2,832.7%
-91.0%$499,000.00$640,000.000.0061Positive News
BPTH
Bio-Path
1.8047 of 5 stars
$2.00
-7.8%
$40.00
+1,900.0%
-94.1%$1.36MN/A0.0010News Coverage
ALLR
Allarity Therapeutics
0.0876 of 5 stars
$0.58
-7.9%
N/A-99.7%$1.38MN/A0.005Gap Down

Related Companies and Tools

This page (NASDAQ:SPRC) was last updated on 5/24/2024 by MarketBeat.com Staff

From Our Partners